These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8299363)

  • 1. Design of novel soft corticosteroids.
    Bodor N
    Curr Probl Dermatol; 1993; 21():11-9. PubMed ID: 8299363
    [No Abstract]   [Full Text] [Related]  

  • 2. Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.
    Druzgala P; Hochhaus G; Bodor N
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):149-54. PubMed ID: 2004037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N; Bodor N; Wu WM
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
    Hochhaus G; Chen LS; Ratka A; Druzgala P; Howes J; Bodor N; Derendorf H
    J Pharm Sci; 1992 Dec; 81(12):1210-5. PubMed ID: 1491342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques.
    Rachwal S; Pop E; Brewster ME
    Steroids; 1996 Sep; 61(9):524-30. PubMed ID: 8883218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contact allergy to topical corticosteroids 1995-2001.
    Rocha N; Silva E; Horta M; Massa A
    Contact Dermatitis; 2002 Dec; 47(6):362-3. PubMed ID: 12581286
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of esterase involved in the metabolism of two corticosteroid soft drugs.
    Samir A; Bodor N; Imai T
    Biochem Pharmacol; 2017 Mar; 127():82-89. PubMed ID: 28017774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P; Howes J
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.
    Sheppard JD; Scoper SV; Samudre S
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):23-7. PubMed ID: 21133792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenal suppression related to inhaled corticosteroids revisited.
    Caballero-Fonseca F; Sánchez-Borges M
    Chest; 2002 Sep; 122(3):1103-4; author reply 1104. PubMed ID: 12226066
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments concerning "Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs".
    Sloan KB; Perrin JH
    J Pharm Sci; 1994 Jul; 83(7):1066-8. PubMed ID: 7965668
    [No Abstract]   [Full Text] [Related]  

  • 15. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.
    Bodor N; Buchwald P
    Curr Pharm Des; 2006; 12(25):3241-60. PubMed ID: 17020532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled corticosteroids and adrenal function.
    Romney J
    Ann Intern Med; 2004 Oct; 141(8):W123; author reply W123. PubMed ID: 15492336
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids.
    Bodor N; Zubovics Z; Kurucz I; Sólyom S; Bodor E
    J Pharm Pharmacol; 2017 Dec; 69(12):1745-1753. PubMed ID: 28980320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?].
    Nos Mateu P
    Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():16-21. PubMed ID: 19087859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.